Plasma protein profiling in patients undergoing coronary artery bypass grafting surgery and clinical significance

• Published in: Oncotarget Vol. 8; no. 36; pp. 60528 - 60538
• Main Authors: Guo, Zhi-Peng, Hou, Hai-Tao, Jing, Rui, Song, Zhen-Guo, Liu, Xiao-Cheng, He, Guo-Wei
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 01.09.2017
• Subjects: Clinical Research Paper; coronary artery disease; platelet factor 4; secreted frizzled-related protein 1; coronary artery bypass grafting
• DOI: 10.18632/oncotarget.16366
• ISSN: 1949-2553

This study was designed to identify the protein profiling in patients with triple vessel coronary artery disease (CAD) undergoing CABG, in order to detect CAD-related differential proteins in these patients. CABG patients with triple vessel disease with/without left main stenosis ( =160) were compared to normal coronary angiographic subjects ( =160). Plasma samples of 20 males and 20 females in each group were analyzed with iTRAQ technique. ELISA test was used to test the chosen proteins from iTRAQ results in plasma samples from a new cohort of the CABG group ( =120, male/femal=61/59) and control ( =120, male/female=60/60). iTRAQ detected 544 proteins with 35 up-regulated and 41 down-regulated (change fold > 1.2 or < 0.83, < 0.05). Three proteins including platelet factor 4 (PF4), coagulation factor XIII B chain (F13B), and secreted frizzled-related protein 1 (sFRP1) were selected for validation by using ELISA that demonstrated significant up-regulation of PF4 and sFRP1 ( < 0.05). There was a positive correlation between these proteins and CAD ( < 0.05) and myocardial infarction history ( < 0.05). Thus, we for the first time have found 76 proteins differentially expressed in plasma of CABG patients. The thrombotic disease/inflammation progress-related protein PF4 and sFRP1, a member of the Wnt/fz signal-transduction pathway and related to myocardial repair, are significantly up-regulated in triple-vessel disease with/without left main stenosis. PF4 may be developed as a biomarker for the diagnosis of the severity of CAD requiring CABG procedure.